Skip to content

PolitiKit

Lobbying by Canadian Generic Pharmaceutical Association (CGPA): its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Organization

Canadian Generic Pharmaceutical Association (CGPA)

Meetings this Parliament
17
With MPs
4
Since Nov 2021
56
Active registrations
1

Most recent reported meeting: Sep 24, 2026.

Registrations in effect

In-house (organization) In effect since Jun 23, 2025

Filed by James Keon, PRESIDENT

Lobbyists

  • James Keon · President Former public office holder

    Formerly Acting Director General, Consumer Affairs, Industry Canada (1994–1994)

    Formerly Regional Director, B.C. and Yukon, Consumer and Corporate Affairs (1991–1993)

    Formerly Director, Intellectual Property, Consumer and Corporate Affairs (1988–1991)

    Formerly Senior Analyst, Consumer Affairs, Consumer and Corporate Affairs (1987–1988)

  • Jeff Connell · Vice President, Corporate Affairs
  • Jody Cox · Vice President, Federal and International Affairs Former public office holder

    Formerly Special Assistant, Communications, Progressive Conservative's Leader Office, House of Commons (2000–2001)

  • Kristin Willemsen · Vice President, Scientific and Regulatory Affairs

Institutions they may lobby: CUSMA Secretariat, Canada Border Services Agency (CBSA), Canadian Heritage (PCH), Canadian International Trade Tribunal (CITT), Competition Bureau Canada (COBU), Employment and Social Development Canada (ESDC), Environment and Climate Change Canada (ECCC), Export Development Canada (EDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), National Defence (DND), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Safety Canada (PS), Public Services and Procurement Canada (PSPC), Senate of Canada, Transport Canada (TC), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (19)
  • Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
  • Provide input into policy discussions with respect to the implementation of a national pharmacare program.
  • Provide input into the Government of Canada's negotiations regarding trade negotiations with respect to pharmaceuticals, counterfeit medicines, and intellectual property.
  • Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
  • Provide input into the Canada-United States-Mexico Agreement (CUSMA).
  • To encourage the Government of Canada to continue to participate in truly international discussions with respect to effective measures to combat substandard and falsified medicines in Canada and around the world.
  • Seeking harmonization of regulatory regimes and administrative processes nationally and internationally.
  • Providing input with respect to the approval pathway for biosimilar medicines by Health Canada.
  • Provide input into the Patented Medicine Prices Review Board (PMPRB) consultations regarding its Policies, Guidelines and Procedures.
  • Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
  • Proposals to enhance transparency of the Health Canada Reconsiderations Policy for drug submissions.
  • Proposals related to Health Canada's Identical Medicinal Ingredient Policy.
  • Participation in Competition Bureau consultations with respect to pharmaceuticals.
  • Participate in Government of Canada consultations with respect to the Regulatory Cooperation Council.
  • Health Canada with respect to user fees for therapeutic product regulatory programs.
  • Health Canada with respect to the process for the approval and renewal of foreign sites for Drug Establishment License (DEL) holders. Related guidance documents include the Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080), the Guidance on Drug Establishment Licences and Drug Establishment Licensing Fees (GUI-0002) and the Guidance on Good Manufacturing Practices for Active Pharmaceutical Ingredients (GUI-0104).
  • Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
  • Health Canada regarding the development of a national pharmacare strategy.
  • Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector.

Registration 776966-548-56. Look it up in the official Registry

Reported meetings

Spreadsheet

  • Reported by James Keon · In-house (organization)

    HealthIndustryIntellectual PropertyInternational Trade

    Official report

  • Reported by James Keon · In-house (organization)

    HealthIndustryInternational Trade

    Official report

  • Reported by James Keon · In-house (organization)

    • Eric Belair · Associate Assistant Deputy Minister, Health Canada (HC)

    HealthIndustryIntellectual Property

    Official report

  • Reported by James Keon · In-house (organization)

    • Nancy Hamzawi · Assistant Deputy Minister, Health Canada (HC)
    • Stefania Trombetti · Assistant Deputy Minister, Health Canada (HC)
    • Eric Belair · Associate Assistant Deputy Minister, Health Canada (HC)

    HealthIndustry

    Official report

  • Reported by James Keon · In-house (organization)

    • Mark Schaan · Acting Senior Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)

    HealthIndustry

    Official report

  • Reported by James Keon · In-house (organization)

    • Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
    • Jean-Sébastien Bock · Director of Policy, Health Canada (HC)

    HealthIndustry

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.